Impact of pharmacy efforts to promote the optimal use of ranitidine in a university teaching hospital

Journal of Pharmacy Technology

Volumn 12, Issue 5, 1996, Pages 207-213

  Sterné, Sharette C ^a   Hayward, Shelly L ^b,c   Ferrill, Mary J ^a   Iteen, Scott A ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANITIDINE;

ARTICLE; CALCULATION; DRUG USE; GASTROINTESTINAL DISEASE; HEALTH CARE; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; INTENSIVE CARE; MEDICAL EDUCATION; PRACTICE GUIDELINE; TEACHING HOSPITAL;

EID: 0029764345     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512259601200505     Document Type: Article

References (20)

1. 2-receptor antagonist use in 30 hospitals. Hosp Formul 1991;26:725-38.
2. Raisch DW, Bootman JL, Larson LN, McGhan WF. Improving antiulcer agent prescribing in a health maintenance organization. Am J Hosp Pharm 1990;47:1766-73.
3. 2-antagonist therapy. Am J Hosp Pharm 1989;46:1183-4.
4. 2-antagonist therapy. Hosp Pharm 1987;22:1205-9.
5. Dannenhoffer MA, Slaughter RL, Hunt SN. Use of concurrent monitoring and preprinted note to modify prescribing of i.v. cimetidine and ranitidine in a teaching hospital. Am J Hosp Pharm 1989; 46:1570-5.
6. 2-receptor antagonists. Drug Intell Clin Pharm 1987;21:885-9.
7. Santora J, Kitrenos JG, Green ER. Pharmacist intervention program focused on i.v. ranitidine therapy. Am J Hosp Pharm 1990;47: 1346-9.
8. Hatton J. Multidisciplinary drug-use evaluation for stress ulcer prophylaxis. Am J Hosp Pharm 1992;49:1440-4.
9. Peters MD, Piscatay NJ, Michael KA, Sjolander JA, Swanson KA, Medina RA. DUE criteria. Clin Pharm 1991;10:787-91.
10. 2-receptor antagonist dosage to meet medical staff approved criteria. Am J Hosp Pharm 1994;51:2152-4.
11. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994;330:377-81.
12. Dobie RL, Rascati KL. Documenting the value of pharmacist interventions. Am Pharm 1994;NS34:50-4.
13. Montazeri M, Cook DJ. Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med 1994;22:1044-8.
14. Chuang LC, Sutton JD, Henderson GT. Impact of a clinical pharmacist on cost savings and cost avoidance in drug therapy in an intensive care unit. Hosp Pharm 1994;29:215-8,221.
15. Strong DK, Tsang GW. Focus and impact of pharmacists' interventions. Can J Hosp Pharm 1993;46:101-8.
16. Rupp MT. Value of community pharmacists' interventions to correct prescribing errors. Ann Pharmacother 1992;26:1580-4.
17. Wilcox CM, Spenney JG. Stress ulcer prophylaxis in medical patients: who, what, and how much? Am J Gastroenterol 1988;83: 1199-211.
18. Package insert. Zantac (ranitidine). Research Triangle Park, NC: Glaxo Inc., June 1993.
19. McEvoy GK, ed. AHFS '93 drug information. Ranitidine monograph. Bethesda, MD: American Society of Hospital Pharmacists, 1993:1853-8.
20. Winter ME. Clinical pharmacokinetics. In: Koda-Kimble MA, Young LL, Guglielmo BJ, Kradjan WA, eds. Handbook of applied therapeutics. 2nd ed. Vancouver, WA: Applied Therapeutics, Inc., 1992:1.7.